Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients

Abstract : Massive loss of lamina propria CD4+ T cells, changes in the lymphatic architecture, and altered intestinal epithelial barrier leading to microbial translocation are the common features of HIV-1 infection and are not fully restored under combined antiretroviral therapy (cART). To better understand determinants of gut mucosal restoration, we have performed phenotypic and gene expression analyses of the gut from HIV-infected patients, naive or treated with cART initiated either at the early phase of the primary infection or later during the chronic phase. We found a depletion of T helper type 22 (Th22) and interleukin-17-producing cells in naive patients. These populations, except Th22 cells, were not restored under cART. Regulatory T cells/Th17 ratio was significantly increased in HIV-infected patients and was inversely correlated to the restoration of CD4+ T cells but not to gut HIV DNA levels. Gene profile analysis of gut mucosal distinguished two groups of patients, which fitted with the timing of cART initiation. In their majority early, but not later treated patients, exhibited conserved intestinal lymphoid structure, epithelial barrier integrity and dendritic cell maturation pathways. Our data demonstrate that early initiation of cART helps to preserve and/or restore lymphoid gut mucosal homeostasis and provide a rationale for initiating cART during the acute phase of HIV infection.
Type de document :
Article dans une revue
Mucosal Immunology, Nature Pub. Group, 2015, 8 (1), pp.127-140. 〈10.1038/mi.2014.50〉
Liste complète des métadonnées

https://hal.inria.fr/hal-01288851
Contributeur : Sandrine Darmigny <>
Soumis le : mardi 15 mars 2016 - 16:29:55
Dernière modification le : vendredi 9 mars 2018 - 16:36:01

Identifiants

Citation

Ayrin Kök, Laurent Hocqueloux, Hakim Hocini, Marie Carrière, Laurent Lefrou, et al.. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunology, Nature Pub. Group, 2015, 8 (1), pp.127-140. 〈10.1038/mi.2014.50〉. 〈hal-01288851〉

Partager

Métriques

Consultations de la notice

167